Herd immunity: challenges and the way forward in the Republic of Korea
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Vaccination is considered to be the most effective measure for preventing the spread of coronavirus disease 2019 (COVID-19). Many countries, including of Korea, are focusing on achieving herd immunity with the goal of reaching a vaccination rate of 70-80%. However, achieving herd immunity does not mean eradicating COVID-19, and the following challenges can occur in the process of achieving herd immunity. First, as the vaccination rate is likely to slow down over time, it is necessary to promote the benefits of vaccination through risk communication strategies and provide incentives for those who have been vaccinated. Second, a booster dose may be required depending on future studies on vaccine-induced immunity. Third, since variants capable of evading immunity and with higher transmissibility can emerge, rapid contract tracing and regular community genomic surveillance could help mitigate the impact of new variants. When the impact of COVID-19 is controlled to the level of seasonal influenza, the current public health measures that have been strictly imposed on society since the beginning of the pandemic will no longer be needed. The overall response strategy to COVID-19 will need to change accordingly, based on evaluations of the level of population immunity. These changes will include more efficient and targeted contact tracing and eased quarantine measures for vaccinated close contacts and travelers. Mask wearing and a minimum of social distancing will still be required in the journey towards the end of the pandemic. The COVID-19 pandemic will end, but the virus will not disappear.
Abstract
Vaccination is considered to be the most effective measure for preventing the spread of coronavirus disease 2019 (COVID-19). Many countries, including of Korea, are focusing on achieving herd immunity with the goal of reaching a vaccination rate of 70-80%. However, achieving herd immunity does not mean eradicating COVID-19, and the following challenges can occur in the process of achieving herd immunity. First, as the vaccination rate is likely to slow down over time, it is necessary to promote the benefits of vaccination through risk communication strategies and provide incentives for those who have been vaccinated. Second, a booster dose may be required depending on future studies on vaccine-induced immunity. Third, since variants capable of evading immunity and with higher transmissibility can emerge, rapid contract tracing and regular community genomic surveillance could help mitigate the impact of new variants. When the impact of COVID-19 is controlled to the level of seasonal influenza, the current public health measures that have been strictly imposed on society since the beginning of the pandemic will no longer be needed. The overall response strategy to COVID-19 will need to change accordingly, based on evaluations of the level of population immunity. These changes will include more efficient and targeted contact tracing and eased quarantine measures for vaccinated close contacts and travelers. Mask wearing and a minimum of social distancing will still be required in the journey towards the end of the pandemic. The COVID-19 pandemic will end, but the virus will not disappear.
참고문헌 (23)
- "Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)" (2020)[URL]
- "Emerging COVID-19 success story: South Korea learned the lessons of MERS" (2021)[URL]
- Shokoohi M, "COVID-19 pandemic: what can the west learn from the east?", Int J Health Policy Manag, 9, pp.436~438 (2020)
- Habib H, "Has Sweden’s controversial covid-19 strategy been successful?", BMJ, 369, pp.m2376~ (2020)
- Khalife Jade, "COVID-19 Herd Immunity in the Absence of a Vaccine: An Irresponsible Approach", Epidemiology and Health, 43, pp.1~12 (2021), 한국역학회[DOI]
- Diderichsen F, "How did Sweden fail the pandemic?", Int J Health Serv (2021)
- "Emerging COVID-19 success story: Vietnam’s commitment to containment" (2020)[URL]
- "Thailand to impose broad lockdown to fight novel coronavirus" (2020)[URL]
- "Coronavirus disease (COVID-19):herd immunity, lockdowns and COVID-19" (2020)[URL]
- Randolph HE, "Herd immunity : understanding COVID-19", Immunity, 52, pp.737~741 (2020)
- Torjesen I, "Covid-19 will become endemic but with decreased potency over time, scientists believe", BMJ, 372, pp.n494~ (2021)
- "Coronavirus pandemic (COVID-19)" (2020)[URL]
- Schaffer DeRoo S, "Planning for a COVID-19vaccination program", JAMA, 323, pp.2458~2459 (2020)
- Anderson RM, "Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination", Lancet, 396, pp.1614~1616 (2020)
- Chia WN, "Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity : a longitudinal study", Lancet Microbe, 2, pp.e240~e249 (2021)
- Post N, "Antibody response to SARS-CoV-2 infection in humans : a systematic review", PLoS One, 15, pp.e0244126~ (2020)
- Choe PG, "Antibody responses 8 months after asymptomatic or mild SARSCoV-2 infection", Emerg Infect Dis, 27, pp.928~931 (2021)
- Hartley GE, "Rapid generation of durable B cell memory to SARSCoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence", Sci Immunol, 5, pp.eabf8891~ (2020)
- Doria-Rose N, "Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19", N Engl J Med, 384, pp.2259~2261 (2021)
- Abu-Raddad LJ, "Effectiveness of the BNT162b2COVID-19 vaccine against the B. 1. 1. 7 and B. 1. 351 variants", N Engl J Med, 385, pp.187~189 (2021)
- Lopez Bernal J, "Effectiveness of COVID-19 vaccines against the B. 1. 617. 2(Delta)variant", N Engl J Med, 385, pp.585~594 (2021)
- "Assessing SARS CoV 2 circulation variants of concern, non pharmaceutical interventions and vaccine rollout in the EU/EEA" (2021)[URL]
- Abdool Karim SS, "New SARS-CoV-2 variants-clinical, public health, and vaccine implications", N Engl J Med, 384, pp.1866~1868 (2021)